Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc (MNPR) is a clinical-stage biopharmaceutical company advancing targeted radiopharmaceuticals for oncology and rare diseases. This page provides investors and researchers with timely updates on clinical trials, regulatory milestones, and scientific advancements.
Access comprehensive coverage of MNPR's innovative pipeline, including MNPR-101 imaging/therapeutic agents and ALXN-1840 for Wilson disease. Track progress across preclinical studies, partnership announcements, and peer-reviewed research developments.
Our curated news includes updates on uPAR-targeted therapies, clinical trial results, manufacturing partnerships, and strategic collaborations. Content is verified for accuracy and relevance to support informed analysis of MNPR's position in precision oncology.
Bookmark this page for streamlined access to Monopar's latest developments. Check regularly for updates on therapeutic candidates, regulatory filings, and scientific publications driving innovation in radiopharmaceutical cancer treatments.
Monopar Therapeutics Inc. reported its first-quarter 2024 financial results and a strategic focus on its radiopharma pipeline. The company initiated the MNPR-101-Zr Phase 1 clinical trial and aims to launch the MNPR-101-RIT Phase 1 trial by Q4 2024 or Q1 2025. Monopar is winding down non-radiopharma programs to concentrate resources on radiopharma assets. The company is well-funded till at least June 30, 2025, with a net loss of $1.6 million for Q1 2024. R&D expenses decreased, while G&A expenses saw a slight drop.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
